Revelation Biosciences Financials
Financial Health Signals
Revelation Biosciences passes 1 of 9 financial strength tests. No profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Revelation Biosciences generates $1.22 in operating cash flow (-$18.3M OCF vs -$15.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Revelation Biosciences (REVB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Revelation Biosciences's EBITDA was -$7.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 7.9% from the prior year.
Revelation Biosciences generated -$18.3M in free cash flow in fiscal year 2024, representing cash available after capex.
Revelation Biosciences reported -$15.0M in net income in fiscal year 2024. This represents a decrease of 12405.6% from the prior year.
Revelation Biosciences earned $-87.68 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 938.9% from the prior year.
Revelation Biosciences held $6.5M in cash against $0 in long-term debt as of fiscal year 2024.
Revelation Biosciences had 174,104 shares outstanding in fiscal year 2024. This represents an increase of 956.2% from the prior year.
Revelation Biosciences invested $3.5M in research and development in fiscal year 2024. This represents a decrease of 14.4% from the prior year.
Revelation Biosciences invested $19K in capex in fiscal year 2024, funding long-term assets and infrastructure.
REVB Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $923K+11.1% | $831K | N/A | $1.7M | N/A | $382K | N/A | $1.5M |
| SG&A Expenses | $1.0M+5.6% | $966K | N/A | $1.1M | N/A | $818K | N/A | $1.5M |
| Operating Income | -$1.9M-8.1% | -$1.8M | N/A | -$2.8M | N/A | -$1.2M | N/A | -$3.0M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0 | $0 | N/A | $0 | N/A | $0 | N/A | $0 |
| Net Income | -$1.9M+14.9% | -$2.2M | N/A | -$2.6M | N/A | -$1.2M | N/A | -$3.0M |
| EPS (Diluted) | $-1.77 | $-40.15 | N/A | $-9.94 | N/A | $-1.91 | N/A | $-0.48 |
REVB Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $12.9M+94.1% | $6.6M-45.8% | $12.2M-14.1% | $14.2M+158.4% | $5.5M-16.6% | $6.6M+223.3% | $2.0M-97.2% | $73.6M |
| Current Assets | $12.8M+95.4% | $6.6M-46.0% | $12.1M-14.1% | $14.1M+161.3% | $5.4M-16.8% | $6.5M+240.2% | $1.9M+4792.3% | $39K |
| Cash & Equivalents | $12.7M+95.5% | $6.5M-45.8% | $12.0M-14.3% | $14.0M+166.4% | $5.3M-15.2% | $6.2M+386.0% | $1.3M-69.2% | $4.1M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.9M-3.1% | $1.9M-65.6% | $5.6M+3.1% | $5.4M+21.3% | $4.5M+1.8% | $4.4M+104.2% | $2.1M-96.9% | $69.9M |
| Current Liabilities | $1.9M-3.1% | $1.9M-65.6% | $5.6M+3.1% | $5.4M+21.3% | $4.5M+1.8% | $4.4M+104.2% | $2.1M-42.7% | $3.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $11.0M+133.7% | $4.7M-29.2% | $6.6M-24.6% | $8.8M+737.9% | $1.1M-52.8% | $2.2M+2339.5% | -$99K-102.7% | $3.7M |
| Retained Earnings | -$46.9M-15.8% | -$40.5M-59.1% | -$25.5M-9.5% | -$23.3M+8.2% | -$25.3M-5.0% | -$24.1M-66.3% | -$14.5M-119.8% | -$6.6M |
REVB Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.6M+57.6% | -$3.7M-87.1% | -$2.0M-16.7% | -$1.7M-81.2% | -$947K+45.3% | -$1.7M+39.9% | -$2.9M-28.8% | -$2.2M |
| Capital Expenditures | N/A | -$18K | N/A | $0 | N/A | N/A | -$16K | $0 |
| Free Cash Flow | N/A | -$3.8M | N/A | -$1.7M | N/A | N/A | -$2.9M-29.6% | -$2.2M |
| Investing Cash Flow | N/A | $18K | N/A | $0 | N/A | N/A | $16K | $0 |
| Financing Cash Flow | $9.1M+147.4% | $3.7M | $0 | $0-100.0% | $5K-99.9% | $4.5M | $0 | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
REVB Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | 61.5% | N/A | N/A | N/A | N/A |
| Return on Assets | -14.8%+18.4pp | -33.3% | N/A | -18.5% | N/A | -17.7% | N/A | -4.1% |
| Current Ratio | 6.92+3.5 | 3.43+1.2 | 2.18-0.4 | 2.62+1.4 | 1.22-0.3 | 1.49+0.6 | 0.89+0.9 | 0.01 |
| Debt-to-Equity | 0.17-0.2 | 0.41-0.4 | 0.84+0.2 | 0.61-3.6 | 4.23+2.3 | 1.96+23.5 | -21.53-40.7 | 19.12 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Revelation Biosciences profitable?
No, Revelation Biosciences (REVB) reported a net income of -$15.0M in fiscal year 2024.
What is Revelation Biosciences's earnings per share (EPS)?
Revelation Biosciences (REVB) reported diluted earnings per share of $-87.68 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Revelation Biosciences's EBITDA?
Revelation Biosciences (REVB) had EBITDA of -$7.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Revelation Biosciences's free cash flow?
Revelation Biosciences (REVB) generated -$18.3M in free cash flow during fiscal year 2024. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Revelation Biosciences's operating cash flow?
Revelation Biosciences (REVB) generated -$18.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Revelation Biosciences's total assets?
Revelation Biosciences (REVB) had $6.6M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Revelation Biosciences's capital expenditures?
Revelation Biosciences (REVB) invested $19K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Revelation Biosciences spend on research and development?
Revelation Biosciences (REVB) invested $3.5M in research and development during fiscal year 2024.
How many shares does Revelation Biosciences have outstanding?
Revelation Biosciences (REVB) had 174,104 shares outstanding as of fiscal year 2024.
What is Revelation Biosciences's current ratio?
Revelation Biosciences (REVB) had a current ratio of 3.43 as of fiscal year 2024, which is generally considered healthy.
What is Revelation Biosciences's debt-to-equity ratio?
Revelation Biosciences (REVB) had a debt-to-equity ratio of 0.41 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Revelation Biosciences's return on assets (ROA)?
Revelation Biosciences (REVB) had a return on assets of -227.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Revelation Biosciences's cash runway?
Based on fiscal year 2024 data, Revelation Biosciences (REVB) had $6.5M in cash against an annual operating cash burn of $18.3M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Revelation Biosciences's Piotroski F-Score?
Revelation Biosciences (REVB) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Revelation Biosciences's earnings high quality?
Revelation Biosciences (REVB) has an earnings quality ratio of 1.22x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.